EU approval for Takeda/DSP's schizophrenia drug Latuda
This article was originally published in Scrip
Executive Summary
Dainippon Sumitomo Pharma (DSP)/Takeda's atypical antipsychotic Latuda (lurasidone) has been approved in the EU for schizophrenia. Representatives for Takeda, which is responsible for commercialization across most of Europe, and of DSP's Sunovion business, which is responsible for the product's launch in the UK, said pricing and specific launch times for Latuda had yet to be determined.